Ewa Mrózek1, Rachel Layman2, Bhuvaneswari Ramaswamy2, Maryam Lustberg2, Andrea Vecchione3, Michael V Knopp4, Charles L Shapiro2. 1. Division of Medical Oncology, The Ohio State University Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH. Electronic address: ewa.mrozek@osumc.edu. 2. Division of Medical Oncology, The Ohio State University Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH. 3. Department of Molecular Virology, Immunology, and Medical Genetics, College of Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH. 4. Division of Imaging Science, Department of Radiology, The Ohio State University, Columbus, OH.
Abstract
BACKGROUND: We hypothesized that adding bevacizumab to neoadjuvant chemotherapy (NCT) with nab-P and carboplatin would increase the rates of pCR in BC patients and that early changes in tumor vascularity imaged by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) would predict pCR. METHODS: Thirty-three women with clinical stage II or III HER2-negative BC received nab-P 100 mg/m2 and carboplatin area under the curve = 2 on days 1, 8, and 15 in combination with bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days. RESULTS: Six patients (18%) achieved pCR, all pCRs occurred in triple-negative BC (TNBC) (pCR = 50% for TNBC). At the end of cycle 2, the changes in relative angiogenic volume were significantly different between responders and nonresponders (P = .001). The major toxicity of this NCT was myelosuppression. CONCLUSION: NCT with weekly nab-P, carboplatin, and biweekly bevacizumab resulted in a pCR rate that was neither superior to the historical data with anthracycline- or taxane-containing NCT nor to carboplatin and taxane combinations in patients with HER2-negative BC. In patients with TNBC, the observed pCR rate was 50%. The early changes in the relative angiogenic volume imaged by DCE-MRI could predict pCR.
BACKGROUND: We hypothesized that adding bevacizumab to neoadjuvant chemotherapy (NCT) with nab-P and carboplatin would increase the rates of pCR in BC patients and that early changes in tumor vascularity imaged by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) would predict pCR. METHODS: Thirty-three women with clinical stage II or III HER2-negative BC received nab-P 100 mg/m2 and carboplatin area under the curve = 2 on days 1, 8, and 15 in combination with bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days. RESULTS: Six patients (18%) achieved pCR, all pCRs occurred in triple-negative BC (TNBC) (pCR = 50% for TNBC). At the end of cycle 2, the changes in relative angiogenic volume were significantly different between responders and nonresponders (P = .001). The major toxicity of this NCT was myelosuppression. CONCLUSION: NCT with weekly nab-P, carboplatin, and biweekly bevacizumab resulted in a pCR rate that was neither superior to the historical data with anthracycline- or taxane-containing NCT nor to carboplatin and taxane combinations in patients with HER2-negative BC. In patients with TNBC, the observed pCR rate was 50%. The early changes in the relative angiogenic volume imaged by DCE-MRI could predict pCR.
Authors: Antonio C Wolff; Donald Berry; Lisa A Carey; Marco Colleoni; Mitchell Dowsett; Matthew Ellis; Judy E Garber; David Mankoff; Soonmyung Paik; Lajos Pusztai; Mary Lou Smith; JoAnne Zujewski Journal: J Clin Oncol Date: 2008-02-10 Impact factor: 44.544
Authors: Nuhad K Ibrahim; Brian Samuels; Ray Page; Dinesh Doval; Kirtikumar M Patel; S C Rao; Madhavan Krishnan Nair; Paul Bhar; Neil Desai; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544
Authors: M Golshan; J E Garber; R Gelman; Nadine Tung; B L Smith; S Troyan; C C Greenberg; E P Winer; P Ryan Journal: Ann Surg Oncol Date: 2010-09-30 Impact factor: 5.344
Authors: Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-04-10 Impact factor: 44.544
Authors: Edith A Perez; Vera J Suman; Kendrith M Rowland; James N Ingle; Muhammad Salim; Charles L Loprinzi; Patrick J Flynn; James A Mailliard; Carl G Kardinal; James E Krook; Abby R Thrower; Daniel W Visscher; Robert B Jenkins Journal: Clin Breast Cancer Date: 2005-12 Impact factor: 3.225
Authors: David Loesch; Nicholas Robert; Lina Asmar; Mary Ann Gregurich; Mark O'Rourke; Shaker Dakhil; Edwin Cox Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: Lori R Arlinghaus; Xia Li; Mia Levy; David Smith; E Brian Welch; John C Gore; Thomas E Yankeelov Journal: J Oncol Date: 2010-09-29 Impact factor: 4.375
Authors: Francisco Rodríguez; Pablo Caruana; Noa De la Fuente; Pía Español; María Gámez; Josep Balart; Elisa Llurba; Ramón Rovira; Raúl Ruiz; Cristina Martín-Lorente; José Luis Corchero; María Virtudes Céspedes Journal: Biomolecules Date: 2022-06-04